{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T04:28:24Z","timestamp":1790742504585,"version":"4.1.0"},"reference-count":32,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2022,11,3]],"date-time":"2022-11-03T00:00:00Z","timestamp":1667433600000},"content-version":"vor","delay-in-days":2,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,11,2]]},"abstract":"Abstract<\/jats:title>\n \n Background<\/jats:title>\n Daptomycin is increasingly used in the treatment of bone and joint infections (BJIs) and may be responsible for daptomycin-induced eosinophilic pneumonia (DIEP), a potentially severe adverse drug reaction. The aim of this study was to describe DIEP in patients treated at a referral center for the management of BJI, and to revisit current definitions of this disease.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n Patients treated from 1 January 2012 to 31 March 2021 were included in a prospective cohort (NCT02817711), in which all potential serious adverse events are prospectively recorded. Patients diagnosed with DIEP were retrospectively analyzed using different definitions.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n In a total of 4664 patients included in the cohort during the study period, 1021 patients (21.9%) received daptomycin, of whom 17 (1.7%) were diagnosed with DIEP. Most patients were male (n = 11 [64.7%]), and periprosthetic joint infection was the commonest BJI (n = 12 [70.6%]). Only 1 patient had bronchoalveolar lavage (BAL) eosinophil count \u226525%, while most patients had peripheral blood eosinophilia (n = 15 [88.2%]). Chest computed tomography (CT) was compatible with eosinophilic pneumonia in 13 of 14 cases (92.9%). All patients recovered upon discontinuation of daptomycin. Using the different definitions available, only a minority of cases fulfilled existing criteria for DIEP. We propose a new algorithm that includes specific CT scan signs, and systemic instead of BAL eosinophilia.<\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n DIEP is a rare event that requires prompt discontinuation of the causative antibiotic. Current criteria to diagnose definite DIEP are too restrictive and not easily applicable in clinical practice. A new algorithm is proposed here (Lyon algorithm) to facilitate the early identification of DIEP.<\/jats:p>\n <\/jats:sec>","DOI":"10.1093\/ofid\/ofac577","type":"journal-article","created":{"date-parts":[[2022,11,3]],"date-time":"2022-11-03T15:22:48Z","timestamp":1667488968000},"source":"Crossref","is-referenced-by-count":20,"title":["Seventeen Cases of Daptomycin-Induced Eosinophilic Pneumonia in a Cohort of Patients Treated for Bone and Joint Infections: Proposal for a New Algorithm"],"prefix":"10.1093","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0284-7080","authenticated-orcid":false,"given":"Truong-Thanh","family":"Pham","sequence":"first","affiliation":[{"name":"Infectious Diseases Department, Croix-Rousse Hospital , Hospices Civils de Lyon, Lyon , France"},{"name":"French Referral Centre for Complex Bone and Joint Infections , Lyon , France"},{"name":"Division of Infectious Diseases, Department of Medicine, Geneva University Hospitals, Geneva , Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6605-4808","authenticated-orcid":false,"given":"Romain","family":"Garreau","sequence":"additional","affiliation":[{"name":"Pharmacy Department, Groupement Hospitalier Nord , Hospices Civils de Lyon, Lyon , France"},{"name":"Laboratoire de Biom\u00e9trie et Biologie Evolutive, Universit\u00e9 Lyon, Unit\u00e9s mixtes de recherche (UMR) Centre National de la Recherche Scientifique (CNRS) 5558 , Villeurbanne , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabien","family":"Craighero","sequence":"additional","affiliation":[{"name":"French Referral Centre for Complex Bone and Joint Infections , Lyon , France"},{"name":"Radiology Department, Croix-Rousse Hospital , Hospices Civils de Lyon, Lyon , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5591-0955","authenticated-orcid":false,"given":"Vincent","family":"Cottin","sequence":"additional","affiliation":[{"name":"National Reference Center for Rare Pulmonary Diseases, Louis Pradel Hospital , Hospices Civils de Lyon, Lyon , France"},{"name":"Claude Bernard University Lyon 1, University of Lyon, Institut national de recherche pour l'agriculture, l'alimentation et l'environnement (INRAE), Infections Virales et Pathologie Compar\u00e9e, Unit\u00e9s mixtes de recherche (UMR) 754, European Reference Networks on Respiratory Diseases (ENR-LUNG) , Lyon , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beno\u00eet Ben","family":"Said","sequence":"additional","affiliation":[{"name":"Severe Cutaneous Adverse Reaction Regional Center and Dermatology Department, Edouard Herriot Hospital , Hospices Civils de Lyon, Lyon , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvain","family":"Goutelle","sequence":"additional","affiliation":[{"name":"Pharmacy Department, Groupement Hospitalier Nord , Hospices Civils de Lyon, Lyon , France"},{"name":"Laboratoire de Biom\u00e9trie et Biologie Evolutive, Universit\u00e9 Lyon, Unit\u00e9s mixtes de recherche (UMR) Centre National de la Recherche Scientifique (CNRS) 5558 , Villeurbanne , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tristan","family":"Ferry","sequence":"additional","affiliation":[{"name":"Infectious Diseases Department, Croix-Rousse Hospital , Hospices Civils de Lyon, Lyon , France"},{"name":"French Referral Centre for Complex Bone and Joint Infections , Lyon , France"},{"name":"Centre International de Recherche en Infectiologie, Inserm U1111, Centre National de la Recherche Scientifique (CNRS) Unit\u00e9s mixtes de recherche (UMR) 5308, \u00c9cole Normale Sup\u00e9rieure (ENS) de Lyon, Universit\u00e9 Claude Bernard Lyon 1 (UCBL) 1, Lyon , France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,11,3]]},"reference":[{"key":"2022112516500987400_ofac577-B1","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1016\/j.arth.2020.12.005","article-title":"Projected economic burden of periprosthetic joint infection of the hip and knee in the United States","volume":"36","author":"Premkumar","year":"2021","journal-title":"J Arthroplasty"},{"key":"2022112516500987400_ofac577-B2","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.otsr.2013.02.011","article-title":"Bacterial epidemiology of osteoarticular infections in a referent center: 10-year study","volume":"99","author":"Titecat","year":"2013","journal-title":"Orthop Traumatol Surg Res"},{"key":"2022112516500987400_ofac577-B3","volume-title":"Cubicin (daptomycin for injection) prescribing information","author":"Cubist Pharmaceuticals"},{"key":"2022112516500987400_ofac577-B4","doi-asserted-by":"crossref","first-page":"e1\u201325","DOI":"10.1093\/cid\/cis966","article-title":"Diagnosis and management of prosthetic joint infection: clinical practice guidelines by the Infectious Diseases Society of America","volume":"56","author":"Osmon","year":"2013","journal-title":"Clin Infect Dis"},{"key":"2022112516500987400_ofac577-B5","doi-asserted-by":"crossref","first-page":"S463","DOI":"10.1016\/j.arth.2018.09.032","article-title":"Hip and knee section, treatment, antimicrobials: proceedings of international consensus on orthopedic infections","volume":"34","author":"Anemuller","year":"2019","journal-title":"J Arthroplasty"},{"key":"2022112516500987400_ofac577-B6","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/s12879-016-1420-7","article-title":"Daptomycin >6 mg\/kg\/day as salvage therapy in patients with complex bone and joint infection: cohort study in a regional reference center","volume":"16","author":"Roux","year":"2016","journal-title":"BMC Infect Dis"},{"key":"2022112516500987400_ofac577-B7","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.jinf.2007.05.180","article-title":"Daptomycin","volume":"55","author":"Enoch","year":"2007","journal-title":"J Infect"},{"key":"2022112516500987400_ofac577-B8","doi-asserted-by":"crossref","first-page":"3991","DOI":"10.1128\/AAC.02344-14","article-title":"Penetration of daptomycin into bone and synovial fluid in joint replacement","volume":"58","author":"Montange","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"2022112516500987400_ofac577-B9","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.ijid.2019.02.005","article-title":"Antibiotic penetration into bone and joints: an updated review","volume":"81","author":"Thabit","year":"2019","journal-title":"Int J Infect Dis"},{"key":"2022112516500987400_ofac577-B10","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1093\/jac\/dky541","article-title":"Genetic polymorphisms of ABCB1 (P-glycoprotein) as a covariate influencing daptomycin pharmacokinetics: a population analysis in patients with bone and joint infection","volume":"74","author":"Bricca","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"2022112516500987400_ofac577-B11","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1093\/jac\/dkab006","article-title":"Population pharmacokinetics of daptomycin in patients with bone and joint infection: minimal effect of rifampicin co-administration and confirmation of a sex difference","volume":"76","author":"Garreau","year":"2021","journal-title":"J Antimicrob Chemother"},{"key":"2022112516500987400_ofac577-B12","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1093\/jac\/dkt512","article-title":"Adverse events, healthcare interventions and healthcare utilization during home infusion therapy with daptomycin and vancomycin: a propensity score-matched cohort study","volume":"69","author":"Shrestha","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"2022112516500987400_ofac577-B13","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1093\/cid\/ciy287","article-title":"Effect of statin coadministration on the risk of daptomycin-associated myopathy","volume":"67","author":"Dare","year":"2018","journal-title":"Clin Infect Dis"},{"key":"2022112516500987400_ofac577-B14","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1086\/652767","article-title":"Daptomycin exposure and the probability of elevations in the creatine phosphokinase level: data from a randomized trial of patients with bacteremia and endocarditis","volume":"50","author":"Bhavnani","year":"2010","journal-title":"Clin Infect Dis"},{"key":"2022112516500987400_ofac577-B15","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1148\/rg.273065051","article-title":"Eosinophilic lung diseases: a clinical, radiologic, and pathologic overview","volume":"27","author":"Jeong","year":"2007","journal-title":"Radiographics"},{"key":"2022112516500987400_ofac577-B16","volume-title":"FDA drug safety communication: eosinophilic pneumonia associated with the use of Cubicin (daptomycin)","author":"US Food and Drug Administration"},{"key":"2022112516500987400_ofac577-B17","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1055\/s-2006-939522","article-title":"Drug-, toxin-, and radiation therapy-induced eosinophilic pneumonia","volume":"27","author":"Solomon","year":"2006","journal-title":"Semin Respir Crit Care Med"},{"key":"2022112516500987400_ofac577-B18","doi-asserted-by":"crossref","first-page":"804","DOI":"10.3109\/00365548.2013.805427","article-title":"Daptomycin-induced acute eosinophilic pneumonia: analysis of the current data and illustrative case reports","volume":"45","author":"Phillips","year":"2013","journal-title":"Scand J Infect Dis"},{"key":"2022112516500987400_ofac577-B19","doi-asserted-by":"crossref","first-page":"447","DOI":"10.2165\/11597460-000000000-00000","article-title":"Eosinophilic pneumonia in patients treated with daptomycin: review of the literature and US FDA adverse event reporting system reports","volume":"35","author":"Kim","year":"2012","journal-title":"Drug Saf"},{"key":"2022112516500987400_ofac577-B20","volume-title":"The drug-induced respiratory disease website","author":"Camus"},{"key":"2022112516500987400_ofac577-B21","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/clpt.1981.154","article-title":"A method for estimating the probability of adverse drug reactions","volume":"30","author":"Naranjo","year":"1981","journal-title":"Clin Pharmacol Ther"},{"key":"2022112516500987400_ofac577-B22","doi-asserted-by":"crossref","first-page":"e9688","DOI":"10.1097\/MD.0000000000009688","article-title":"Drug-induced eosinophilic pneumonia: a review of 196 case reports","volume":"97","author":"Bartal","year":"2018","journal-title":"Medicine (Baltimore)"},{"key":"2022112516500987400_ofac577-B23","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.jiac.2016.09.001","article-title":"Eosinophilic pneumonia caused by daptomycin: six cases from two institutions and a review of the literature","volume":"23","author":"Hirai","year":"2017","journal-title":"J Infect Chemother"},{"key":"2022112516500987400_ofac577-B24","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1177\/1060028021991943","article-title":"High-dose daptomycin and clinical applications","volume":"55","author":"Jones","year":"2021","journal-title":"Ann Pharmacother"},{"key":"2022112516500987400_ofac577-B25","doi-asserted-by":"crossref","first-page":"446","DOI":"10.3390\/antibiotics10040446","article-title":"Risk factors of daptomycin-induced eosinophilic pneumonia in a population with osteoarticular infection","volume":"10","author":"Soldevila-Boixader","year":"2021","journal-title":"Antibiotics (Basel)"},{"key":"2022112516500987400_ofac577-B26","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s13756-016-0158-8","article-title":"Daptomycin-induced eosinophilic pneumonia\u2014a systematic review","volume":"5","author":"Uppal","year":"2016","journal-title":"Antimicrob Resist Infect Control"},{"key":"2022112516500987400_ofac577-B27","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1164\/rccm.2112056","article-title":"Idiopathic acute eosinophilic pneumonia: a study of 22 patients","volume":"166","author":"Philit","year":"2002","journal-title":"Am J Respir Crit Care Med"},{"key":"2022112516500987400_ofac577-B28","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1097\/00005792-199611000-00004","article-title":"Acute eosinophilic pneumonia. A summary of 15 cases and review of the literature","volume":"75","author":"Pope-Harman","year":"1996","journal-title":"Medicine (Baltimore)"},{"key":"2022112516500987400_ofac577-B29","doi-asserted-by":"crossref","first-page":"2997","DOI":"10.1001\/jama.292.24.2997","article-title":"Acute eosinophilic pneumonia among US military personnel deployed in or near Iraq","volume":"292","author":"Shorr","year":"2004","journal-title":"JAMA"},{"key":"2022112516500987400_ofac577-B30","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.ccm.2016.04.015","article-title":"Eosinophilic lung diseases","volume":"37","author":"Cottin","year":"2016","journal-title":"Clin Chest Med"},{"key":"2022112516500987400_ofac577-B31","doi-asserted-by":"crossref","first-page":"2819","DOI":"10.1007\/s00330-020-07347-x","article-title":"The sensitivity and specificity of chest CT in the diagnosis of COVID-19","volume":"31","author":"Kovacs","year":"2021","journal-title":"Eur Radiol"},{"key":"2022112516500987400_ofac577-B32","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/S0140-6736(22)00009-5","article-title":"Ground glass opacities are not always COVID-19: a case of acute eosinophilic pneumonitis caused by daptomycin","volume":"399","author":"Valaiyapathi","year":"2022","journal-title":"Lancet"}],"container-title":["Open Forum Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ofid\/advance-article-pdf\/doi\/10.1093\/ofid\/ofac577\/46780763\/ofac577.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/9\/11\/ofac577\/47265984\/ofac577.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/9\/11\/ofac577\/47265984\/ofac577.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,25]],"date-time":"2022-11-25T16:50:40Z","timestamp":1669395040000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ofid\/article\/doi\/10.1093\/ofid\/ofac577\/6795112"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,1]]},"references-count":32,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022,11,2]]}},"URL":"https:\/\/doi.org\/10.1093\/ofid\/ofac577","relation":{},"ISSN":["2328-8957"],"issn-type":[{"value":"2328-8957","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,11,1]]},"published":{"date-parts":[[2022,11,1]]},"article-number":"ofac577"}}